| Literature DB >> 23877090 |
Connye N Kuratko1, Erin Cernkovich Barrett, Edward B Nelson, Norman Salem.
Abstract
Childhood is a period of brain growth and maturation. The long chain omega-3 fatty acid, docosahexaenoic acid (DHA), is a major lipid in the brain recognized as essential for normal brain function. In animals, low brain DHA results in impaired learning and behavior. In infants, DHA is important for optimal visual and cognitive development. The usual intake of DHA among toddlers and children is low and some studies show improvements in cognition and behavior as the result of supplementation with polyunsaturated fatty acids including DHA. The purpose of this review was to identify and evaluate current knowledge regarding the relationship of DHA with measures of learning and behavior in healthy school-age children. A systematic search of the literature identified 15 relevant publications for review. The search found studies which were diverse in purpose and design and without consistent conclusions regarding the treatment effect of DHA intake or biomarker status on specific cognitive tests. However, studies of brain activity reported benefits of DHA supplementation and over half of the studies reported a favorable role for DHA or long chain omega-3 fatty acids in at least one area of cognition or behavior. Studies also suggested an important role for DHA in school performance.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23877090 PMCID: PMC3738999 DOI: 10.3390/nu5072777
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Observational studies reporting docosahexaenoic acid (DHA)-related outcomes of cognition and behavior in children.
| Reference | Study Design | Participants | Outcome Measures | Results | |
|---|---|---|---|---|---|
| Cognition | Behavior | ||||
| Boucher
| Prospective | Neuropsychological Assessments | |||
| Kirby
| Cross-Sectional | Cheek cell DHA levels were positively associated with non-verbal IQ (KBIT-2) | Cheek cell DHA levels were negatively associated with teacher rated hyperactivity and total difficulties (SDQ) | ||
| Bakker
| Prospective | There was no association between cord blood DHA levels and cognitive performance (K-ABC) | |||
Abbreviations: California Verbal Learning Test (CVLT), Continuous Recognition Task (CRT), Developmental Coordination Disorder Questionnaire (DCDQ), Event-Related Potentials (ERP), Kaufman Assessment Battery for Children (K-ABC), Kaufman Brief Intelligence Test (KBIT), Matching Familiar Figures Task (MFFT), Test of Everyday Attention for Children (TEA-Ch), Strengths Difficulties Questionnaire (SDQ), Swanson, Nolan, and Pelham (SNAP), Wechsler Individual Achievement Test (WIAT), Wechsler Intelligence Scales for Children (WISC), Working Memory Test Battery for Children (WMTB-C).
Clinical trials of DHA supplementation on outcomes of cognition and behavior in children.
| Reference | Study Design | Participants | Intervention | Time | Outcome | Results | |
|---|---|---|---|---|---|---|---|
| Cognition | Behavior | ||||||
| Baumgartner
| RCT | 1. Placebo | 38 | ||||
| Dalton
| RCT | 1. Control spread | 24 | ||||
| Hamazaki
| RCT | 1. Placebo capsules | 12 | ||||
| Itomura
| RCT | 1. Control foods | 12 | ||||
| Kennedy
| RCT | Placebo capsules | 8 | ||||
| Kirby
| RCT | Placebo capsules | 16 | In the ITT analysis, fish oil had no effect on IQ, reading and spelling, working memory, attention, visual attention, impulsivity, or handwriting process | |||
| McNamara
| RCT | Placebo capsules | 8 | ||||
| Muthayya
| RCT | 52 | All four groups improved in short-term memory, retrieval ability, fluid reasoning, cognitive speediness, and the Mental Processing Index compared with baseline | ||||
| Richardson
| RCT | Placebo capsules | 16 | For children with baseline reading scores ≤33rd% tile, DHA improved parent-rated behavior including oppositional ( | |||
| Ryan
| RCT | Placebo capsules | 16 | In the ITT analysis, DHA had no effect on cognition | |||
| Sinn
| Open label | Fish oil: 558 mg EPA | 12 | Fish oil improved reading ( | Behavior was not assessed at week 12 (teachers who completed the CBRS at baseline left the school) | ||
| The NEMO Study Group 2007 [ | RCT | 52 | |||||
Abbreviations: Barratt Impulsiveness Scale (BIS-II), British Ability Scale (BAS), Cognition Drug Research (CDR), Computerized Penmanship Evaluation Tool (ComPET), Conners’ Behavior Ratings Scales (CBRS), Conners’ Parent Rating Scales (CPRS), Conners’ Teacher Rating Scales (CTRS), Functional Magnetic Resonance Imaging (fMRI), Hostility-Aggression Questionnaire for Children (HAQ-C), Hopkins Verbal Learning Test (HVLT), Identical-Pairs verson of the Continuous Performance Task (CPT-IP), Intention-to-treat (ITT), Kaufman Assessment Battery (K-ABC), Kaufman Brief Intelligence Test (KBIT), Matching Familiar Figures Task (MFFT), Neuropsychological Assessment tool (NEPSY), Picture Frustration (PF), Ray Auditory Verbal Learning Test (RAVLT), Strengths and Difficulties Questionnaire (SDQ), Swanson, Nolan, and Pelham (SNAP), Test of Everyday Attention for Children (TEA-Ch), Wechsler Individual Achievement Test (WIAT), Wechsler Intelligence Scales for Children (WISC), Wide Range Achievement Test (WRAT), Working Memory Test Battery for Children (WMTB-C).
DHA status reported in clinical trials of DHA supplementation in children.
| Reference | Time Point | Placebo | Treatment | Biomarker | ||
|---|---|---|---|---|---|---|
| Dalton
| Baseline | % of total fatty acids (PC in RBCs) | ||||
| Endpoint | 2.81 ± 0.70 | 3.71 ± 0.66 | ||||
| Baseline | % of total fatty acids (PE in RBCs) | |||||
| Endpoint | 7.77 ± 2.16 | 8.98 ± 2.61 | ||||
| Baseline | % of total fatty acids (PC + PE in RBCs) | |||||
| Endpoint | 10.58 | 12.69 | ||||
| Hamazaki
| Baseline | 4.4 ± 0.9 | 4.4 ± 1.1 | % of total fatty acids (phospholipid fraction in RBCs) | ||
| Endpoint | 4.9 ± 1.2 | 7.8 ± 1.1 | ||||
| Itomura
| Baseline | 6.4 ± 0.9 | 6.1 ± 0.9 | % of total fatty acids (phospholipid fraction in RBCs) | ||
| Endpoint | 6.6 ± 0.9 | 7.1 ± 1.8 | ||||
| Kennedy
| ||||||
| Kirby
| Baseline | 0.07 ± 0.007 | 0.08 ± 0.009 | % of total fatty acid methyl esters (buccal cell sample) | ||
| Endpoint | 0.20 ± 0.16 | 0.37 ± 0.23 | ||||
| Richardson
| ||||||
| Ryan
| Baseline | 1.0 ± 0.34 | 1.0 ± 0.34 | % of total fatty acids (capillary whole blood) | ||
| Endpoint | 1.1 ± 0.40 | 3.3 ± 1.54 | ||||
| Sinn
| ||||||
| Baumgartner
|
|
|
|
| ||
| Baseline | 3.07 ± 0.69 | 3.07 ± 0.64 | 3.05 ± 0.63 | 3.01 ± 0.58 | % of total fatty acids (phospholipid fraction in RBCs) | |
| Endpoint | 3.79 ± 0.96 | 3.83 ± 1.06 | 5.94 ± 1.71 | 5.90 ± 2.11 | ||
| McNamara
|
|
|
| |||
| Baseline | 3.3 ± 1.3 | 3.3 ± 1.3 | 3.3 ± 1.3 | % of total fatty acids (RBC) | ||
| Endpoint | 2.5 ± 1.6 | 7.5 ± 1.3 | 10.3 ± 1.5 | |||
| Muthayya
| Low Micro/Low Omega-3 | Low Micro/High Omega-3 | High Micro/Low Omega-3 | High Micro/High Omega-3 | ||
| Baseline | 3.3 ± 0.9 | 3.2 ± 0.9 | 3.2 ± 0.8 | 3.2 ± 0.7 | % of total fatty acids (phospholipid fraction in RBCs) | |
| Endpoint | 3.6 ± 1.0 | 5.2 ± 1.2 | 3.6 ± 0.8 | 5.2 ± 1.2 | ||
| The NEMO Study Group2007 [ |
|
|
|
| ||
| Baseline | 33.2 ± 11.0 | 35.2 ± 10.4 | 31.1 ± 10.6 | 32.7 ± 10.3 | Plasma (μg/mL) | |
| Endpoint | 38.4 ± 14.0 | 36.8 ± 8.5 | 47.4 ± 12.7 | 47.4 ± 10.7 | ||
Abbreviations: Red blood cells (RBCs), Phosphatidylcholine (PC), Phosphatidylethanolamine (PE), Not reported (NR).